PHASE II TRIAL OF 9-AMINOCAMPTOTHECIN IN ADVANCED CUTANEOUS T CELL LYMPHOMA
OBJECTIVES: I. Assess the antitumor activity of aminocamptothecin (9-AC) administered by
72-hour infusion in patients with advanced cutaneous T-cell lymphoma. II. Assess the toxic
effects of 9-AC administered on this schedule.
OUTLINE: Single-Agent Chemotherapy. Aminocamptothecin, 9-AC, NSC-603071.
PROJECTED ACCRUAL: A total of 30 patients will be accrued; if no more than 1 response is
seen in the first 15 patients, the study will close. Probable duration of study is 18
Primary Purpose: Treatment
John R. Murren, MD
United States: Federal Government
|Robert H. Lurie Comprehensive Cancer Center, Northwestern University||Chicago, Illinois 60611|
|New England Medical Center Hospital||Boston, Massachusetts 02111|
|Yale Comprehensive Cancer Center||New Haven, Connecticut 06520-8028|